This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Lymphoma	IL-17A; IL-17 receptor C (IL17RC); VEGF	<p>Mouse studies suggest IL-17A inhibitors could help treat VEGF inhibitor-resistant cancers. In mouse models of murine lymphoma, IL-17a levels were higher in VEGF inhibitor-resistant tumors than in VEGF inhibitor-sensitive tumors. In mice with resistant lymphomas treated with anti-Vegf antibody, <i>Il17rc</i> deficiency or co-treatment with an anti-IL-17a antibody decreased tumor growth compared with intact <i>Il17rc</i> or no co-treatment. Future studies could include testing IL-17A inhibitors in models bearing VEGF inhibitor-resistant xenograft tumors. At least eight companies have antibodies against IL-17A or IL-17 receptor (IL17R; IL17RA) in Phase I through Phase III testing to treat multiple autoimmune and/or inflammatory indications.</p> <p>SciBX 6(31); doi:10.1038/scibx.2013.825 Published online Aug. 15, 2013</p>	Patent and licensing status undisclosed	<p>Chung, A.S. <i>et al. Nat. Med.</i>; published online Aug. 4, 2013; doi:10.1038/nm.3291 Contact: Napoleone Ferrara, University of California San Diego, La Jolla, Calif. e-mail: nferrara@ucsd.edu</p>